Limbic selected to FDA pilot, will test voice AI therapy with Medicare enrollees

The Food and Drug Administration (FDA) is tapping Limbic, the maker of an AI-led behavioral health tool, as an early participant in its TEMPO pilot. | Through TEMPO, Limbic will gather real-world data on outcomes, safety and how patients use the service, which will eventually support its application when it is ready to seek FDA approval.